NCT Number: NCT00150202
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.
Looking for future studies?
Notify MeKey information
Age range
50 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Pfizer Investigational Site, Nagoya, Aichi-ken, Japan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Wet AMD, Visual Acuity from 20/320 to 20/40
Exclusion criteria
- Diabetic retinopathy, laser coagulation history
Treatment and study plan
Primary outcomes
-
Visual aquity change from the baseline to 54 weeks after the first treatment is expected to be similar to that seen in the Western studies.
Secondary outcomes
-
Safety profile of pegaptanib including side effects and lab test from the baseline to 54 weeks after the first treatment. Blood concentration of the drug from the baseline to 54 weeks after the irst treatment.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
Clinical Study Of EYE001 In Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
Important dates
- Study start
- 2004
- Study completion
- 2006
- First posted
- Sep 8, 2005
- Registry last updated
- May 7, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
NCT06305416
Cardiovascular Diseases, Diabetes Complications
Dhaka, Bangladesh
View Trial DetailsA Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041
Eye Diseases, Geographic Atrophy
Gilbert, Arizona, United States
View Trial DetailsStudy of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
NCT04567303
Eye Diseases, Macular Degeneration
Mesa, Arizona, United States
View Trial DetailsPatient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia
NCT07779356
Cardiovascular Diseases, Diabetes Complications
Easton, Maryland, United States
View Trial Details